001360.KO Samsung Pharm
- Market cap
- KRW 119B
- P/E
- 9.3x
- P/B
- 1.64x
- ROE
- -132.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 001360.KO undervalued?
Graham number001360.KO trades 17.4% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Samsung Pharm fundamental analysis
No fundamental analysis for Samsung Pharm yet.
Samsung Pharm stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestiv…
Full company profileSamsung Pharm financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Samsung Pharm annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 48.2B | 41.9B | 46.5B | 44.6B | 48.3B | 54.9B | 51.8B | 52.0B | 44.3B | 46.1B | 37.8B |
| Gross Profit | 7.61B | 5.08B | 8.59B | 9.40B | 10.5B | 9.28B | 24.6B | 23.0B | 19.8B | 14.0B | 16.7B |
| Operating Income | -9.59B | -6.88B | -4.78B | -5.22B | -9.80B | -18.1B | -14.0B | -18.0B | -14.8B | -18.1B | -13.8B |
| EBITDA | - | -4.46B | 3.10B | 12.0B | -33.6B | -36.6B | -22.0B | -21.7B | -11.7B | 14.2B | 9.55B |
| Net Income | -21.6B | -7.54B | -2.08B | 6.89B | -39.9B | -40.3B | -25.1B | -24.8B | -14.1B | 11.5B | -95.8B |
| EPS | - | -167 | -36 | 117 | -585 | -541 | -337 | -334 | -150 | 123 | -1,017 |
| Balance Sheet | |||||||||||
| Total Assets | 138B | 154B | 161B | 169B | 179B | 145B | 118B | 93.5B | 128B | 167B | 121B |
| Total Liabilities | 55.9B | 60.3B | 29.0B | 25.7B | 56.8B | 18.2B | 15.3B | 15.9B | 22.6B | 46.4B | 48.8B |
| Shareholders' Equity | 82.4B | 93.9B | 132B | 143B | 122B | 127B | 103B | 77.6B | 106B | 121B | 72.3B |
| Cash & Short-term Investments | 5.39B | 2.93B | 3.15B | 5.05B | 26.4B | 26.1B | 36.0B | 4.28B | 7.39B | 11.2B | 4.56B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.94B | 5.15B | -6.52B | -2.43B | -2.55B | -7.16B | -1.91B | -27.7B | -17.3B | -10.1B | -7.15B |
| Capital Expenditure | 33.2B | 6.11B | 2.61B | 13.9B | 7.15B | 4.07B | 3.03B | 12.8B | 381M | 12.8B | 1.85B |
| Free Cash Flow | - | -848M | -10.2B | -16.3B | -9.71B | -11.2B | -4.95B | -40.4B | -17.7B | -22.8B | -8.99B |
| Ratios | |||||||||||
| ROE | -26.2% | -8.0% | -1.6% | 4.8% | -32.7% | -31.6% | -24.5% | -32.0% | -13.3% | 9.5% | -132.5% |
| ROA | -15.6% | -4.9% | -1.3% | 4.1% | -22.3% | -27.7% | -21.3% | -26.5% | -11.0% | 6.9% | -79.1% |
| Net Profit Margin | -44.8% | -18.0% | -4.5% | 15.4% | -82.6% | -73.4% | -48.4% | -47.8% | -31.8% | 25.1% | -253.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Samsung Pharm dividends
Samsung Pharm has not paid dividends in the last 9 fiscal years.
Last stock split: 551:504 on May 2, 2018.
Who owns Samsung Pharm
- Insiders 10.47%
- Institutions 0.65%
- Public & others 88.89%
- Shares outstanding 94.1M
- Free float 52.4M
Samsung Pharm company profile
- Company name
- Samsung Pharm
- Ticker
- 001360.KO
- ISIN
- KR7001360007
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 10, Yakgongdan 4-gil, Hwaseong-si, South Korea, 18622
- Phone
- 82 3 1353 6681
- Website
- sspharm.co.kr
About Samsung Pharm
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, enzyme, mixed vitamins, antibiotics, and others. The company also provides medicines for the digestive system, medicines for liver disorders, medicines for the circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, cold medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
Samsung Pharm management
2- Sung Tag JungCEO & Chairman · born 1977
- HwaYeong ParkInternal Director & VP